Germacrene A ( 3 ) has been proposed to be an intermediate in the cyclization of farnesyl diphosphate ( 1 ) to the sesquiterpene hydrocarbon (+)-aristolochene ( 2 ). Under normal circumstances, however, neither 3 nor any other intermediate is released from the cyclase active site. When the anomalous substrate (7 R )-6,7-dihydrofarnesyl diphosphate ( 5 ) is incubated with aristolochene synthase from Aspergillus terreus, the resultant dihydrogermacrene ( 6 ) cannot be further cyclized and is released from the active site. The structure of the abortive cyclization product, m / z 206, was confirmed as dihydrogermacrene ( 6 ) by direct GC−MS comparison with an authentic synthetic sample prepared from (−)-(3 S )-β-citronellol.
No takes yet. Share an insight, caveat, or question.
Cane et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: